Diagnostic yield, safety, and molecular-era clinical utility of stereotactic biopsy for brainstem lesions: a contemporary systematic review and meta-analysis - Report - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Evaluating the Diagnostic Effectiveness, Safety, and Clinical Relevance of Stereotactic Biopsy for Brainstem Lesions: A Systematic Review and Meta-Analysis of Recent Evidence
Clinical Report: Evaluating the Diagnostic Effectiveness of Stereotactic Biopsy
Overview
This systematic review and meta-analysis evaluates the diagnostic yield and safety of stereotactic biopsy for brainstem lesions. The findings indicate a high diagnostic yield of 93.5% with manageable complication rates.
Background
Stereotactic biopsy is a critical tool in neuro-oncology for diagnosing brainstem lesions, which pose significant diagnostic challenges due to their complex anatomy. Accurate tissue diagnosis is essential for guiding treatment decisions, particularly in cases where imaging does not provide definitive answers.
Data Highlights
Measure
Value
95% CI
Diagnostic Yield
93.5%
91.5%–95.0%
Overall Complications
10.5%
8.5%–12.8%
Permanent Neurological Morbidity
0.83%
0.22%–3.03%
Procedure-Related Mortality
0.62%
0.31%–1.11%
Key Findings
Stereotactic biopsy achieved a diagnostic yield of 93.5% across selected cohorts.
Overall complications from the procedure were reported at 10.5%.
Permanent neurological morbidity was estimated at 0.83%.
Procedure-related mortality was low, at 0.62%.
Diagnostic yield was inversely associated with study size.
Variability in outcomes was noted based on population, technique, and definitions of success.
Clinical Implications
The high diagnostic yield of stereotactic biopsy supports its use in managing brainstem lesions. Clinicians should consider the associated risks in the context of the data presented.
Conclusion
Stereotactic biopsy for brainstem lesions demonstrates a high diagnostic yield with low mortality and morbidity rates.
